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Pancreatitis in adult with acute lymphoblastic leukemia
using L-asparaginase and simvastatin: case report and
systematic review
Pancreatite em adulto com leucemia linfoblástica aguda usando L-asparaginase e
sinvastatina: relato de caso e revisão sistemática
Renne Rodrigues1*, Diogo D. Gavarrete2, Érika A. T. Bernardi3, Eduardo C. Munhoz4.
ABSTRACT
Context: Acute pancreatitis is a inflammatory process of the pancreas. It can be caused by gallstones,
metabolic disorders, associated or not with alcohol abuse, or medication. Case Report: A 38-year-old
man was admitted to the hospital because of worsening of nausea, abdominal pain, dizziness and white
stool. Patient was diagnosed with severe acute pancreatitis. After six days of hospitalization, patient
progressed into hypotension and severe bradycardia, and died. The patient used simvastatin chroni-
cally, and was in treat with L-asparaginase, both drugs related to the occurence of acute pancreatitis
separately. Naranjo´s probability scale of adverse drug reaction established the causality between these
medications and acute pancreatitis as probable. However, due to the absence of reports of causality, the
acute pancreatitis is associated with to the use of L-asparaginase with possible drug interactions with
simvastatin. Conclusion: It is very important to monitor patients treated with L-asparaginase, through
careful observation of clinical signs and laboratory follow-up, as well as verification of other medications
in use. The AP may have different levels of severity, being indispensable the quick diagnosis and early
treatment.
Key Words: Precursor Cell Lymphoblastic Leukemia-Lymphoma. Asparaginase. Pancreatitis. Simvastatin.
Drug Interaction.
RESUMO
Contexto: Pancreatite aguda é um processo inflamatório do pâncreas. É causada por cálculos biliares,
desordens metabólicas, associadas ou não ao uso abusivo de álcool, ou medicamentos. Relato do
Caso: Homem de 38 anos foi admitido no hospital em razão do agravamento de náuseas, dor abdomi-
nal, tontura e fezes brancas. O paciente foi diagnosticado com pancreatite aguda. Após seis dias de
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Introduction
Acute pancreatitis is an inflammatory proc-
ess of the pancreas, usually reversible. It can be
caused by gallstones, metabolic disorders, associ-
ated or not with alcohol abuse, or medication.1,2
The clinical diagnosis of acute pancreatitis is based
on characteristic abdominal pain and nausea, com-
bined with elevated serum levels of pancreatic en-
zymes (amylase and lipase) and abdominal imaging
by computed tomography (CT), magnetic resonance
imaging, or transabdominal ultrasonography.2
L-asparaginase is a strategic medicine for the
cure of acute lymphoblastic leukemia (ALL) in adults,
increasing overall survival.3 However, this benefit
brings with it potential side effects such as anaphy-
laxis and problems in the liver and pancreas.4 The
pancreatitis may develop into pancreatic pseudo-
cyst, panniculitis, among other complications such
as infections. There is also the risk of developing
chronic sequelae, such as prolonged pancreatic exo-
crine insufficiency.1,5-8
Case report
A 38-year-old man, caucasian, with dyslipi-
demia, treated with simvastatin 20mg once a day
for more than one year, with no history of alcohol-
ism. He was diagnosed with B-cell ALL, was treated
with the protocol CALGB 88116, which includes L-
asparaginase Escherichia coli-derived drug twice a
week, six applications in the induction course, and
four times during early intensification. Patient com-
pleted the induction featuring complete remission,
with 1.2% of immature cells in bone marrow, be-
gan the early intensification phase one month after
induction. Early intensification also occurs in asso-
ciation with cyclophosphamide, cytarabine, dexam-
ethasone, vincristine and intrathecal methotrexate.
On the 25th day of the early intensification,
three days after the 11th dose of L-asparaginase,
the patient developed nausea and malaise, thus did
not return to hospital and did not get the last appli-
cation of L-asparaginase. On the 28th day, six days
after the 11th dose of L-asparaginase, he returns to
the hospital, reporting worsening of nausea, abdomi-
nal pain, dizziness and white stool. Exams performed
in the emergency lab showed abnormal levels of
amylase, lipase, lactate dehydrogenase (LDH), C-
reactive protein (CRP) and total bilirubin (Table 1),
and the patient was admitted with suspected pan-
creatitis. When the patient was hospitalized more
tests were performed, gamma glutamyl transferase
and prothrombin time presents normal results.
A CT scan showed pancreas increased vol-
ume without significant necrosis or evidence of gall-
stones. Differential diagnosis confirmed the hypoth-
esis of Acute Pancreatitis (AP), discarding hyper-
triglyceridemia, alcohol and gallstones as causative
agents. This cause was associated with medications,
specifically L-asparaginase with possible participa-
tion of simvastatin. The Naranjo probability scale9
was applied in order to establish the causality of
the adverse drug reaction occurrence. According to
this scale, the probability of asparaginase and
simvastatin being the cause of pancreatitis was clas-
sified as probable, reaching 5 points.
To establish the risk of severe disease the
Ranson´s Score was performed, with basis in white-
cell count, age and levels of LDH and alanine ami-
notransferase10. Score 5 was obtained, indicating
risk of death of 40%. Score APACHE II was carried
internação, paciente progrediu com hipotensão e bradicardia severa, evoluindo à óbito. O paciente fazia
uso crônico de sinvastatina, e estava em tratamento com L-asparaginase, ambos fármacos, de modo
separado, são relacionados com a ocorrência de pancreatite aguda severa. O algoritmo de Naranjo para
estabelecimento de reação adversa a medicação classificou a causalidade entre as medicações citadas e
a pancreatite aguda como provável. Porém, em razão da ausência relatos dessa causalidade, associa-se
a pancreatite aguda ao uso de L-asparaginase, com possível interação medicamentosa com sinvastatina.
Conclusão: É de suma importância o acompanhamento clínico e laboratorial de pacientes em uso de L-
asparaginase para sinais de pancreatite aguda, sendo imprescindível o rápido diagnóstico e tratamento
precoce.
Palavras-chave: Leucemia-Linfoma Linfoblástico de Células Precursoras. Asparaginase. Pancreatite.
Sinvastatina. Toxicidade de Drogas.
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out, showing 18 points, equivalent to a 25% risk of
death, therefore, considered as severe AP.
The patient was kept in absolute fasting, be-
ing hydrated and corrected hypokalemia (still pre-
senting thombocitopenia and leukopenia). Improve-
ment in the second day of hospitalization was sub-
jective, and started on the 4th day enteral nutrition.
On 5th day of hospitalization, there was an
improvement of amylase and LDH, but there was a
rise of CRP (Table 1), associated with clinical suspi-
cion of infection. For this reason antibiotic treat-
ment (meropenem) was started. Throughout the day
the patient developed worsening of respiratory pat-
tern, stable tachycardia, repetitive cases of hypogly-
cemia and confusion, supporting suspicion of sepse
for AP infected. Patient was immediately transferred
to Intensive Care Unit.
Overnight, patient had hypotension and meta-
bolic acidosis, was intubated and medicated for aci-
dosis and also treated with vasoactive drugs. In the
morning of 6th day of hospitalization, patient pro-
gressed into hypotension, severe bradycardia, and
died.
Discussion
The most common causes for AP are alcohol-
ism and presence of gallstone2,10, but these hypoth-
eses were discarded after the differential investiga-
tion. The real role of hypertriglyceridemia as cause
of AP is unknown, but the patient levels in the hos-
pitalized period, although high, don’t support this
theory. The AP was attributed to medications in use,
specifically L-asparaginase, with possible participa-
tion of simvastatin.
A systematic search was conducted in the
main electronic databases (PubMed, Cochrane Li-
brary, Lilacs, and SciELO), in order to find work to
Table 1. Exams performed in hospitalization period, six days after the 11th dose of L-asparaginase.
Days of hospitalization
Exams (RR) 1st 2nd 5th
Amylase (30-110U/L) 498 119 101
Lipase (23-300U/L 6.307 1.582 1.196
LDH (313-618U/L 2.221 1813 1.239
CRP (0-1mg/dL 18,1 21,6 45,5
Total bilirubin (0,20-1,30mg/dL) 1,99 3,47 2,70
Platelets (150.000-400.000mm³) 402.000 10.000 95.000
White-cell count (4.000-11.000mm³) 9.320 3.300 5.200
Hematocrit (42,5-52,9%), 49,5 30,2 33,1
Hemoglobin (14,3-18,3g/dL) 16,5 9,2 9,7
Phosphorus (2,5-4,5mg/dL) - 11,6 -
Magnesium (1,6-2,3mg/dL) - 3,7 -
Potassium (3,5-5,1mEq/L) - 5,9 -
Calcium (8,4-10,2mg/dL) - 5,4 -
Glucose (74-106mg/dL). - 38 35
Triglycerides* - 317 -
RR: Reference range. LDH: Lactate dehydrogenase. CRP: C-reactive protein. *RR of triglycerides: normal <150mg/dL, high limit
151-199mg/dL, high 200-499mg/dL.
http://www.revistas.usp.br/rmrp / http://revista.fmrp.usp.br 93
Rodrigues R, Gavarrete DD, Bernardi EAT, Munhoz ED.
Pancreatitis in adult using L-asparaginase and simvastatin.
Medicina (Ribeirão Preto. Online) 2016;49(1): 90-4
report the occurrence of pancreatitis in association
with the use of asparaginase and/or simvastatin in
humans. For research no limits were applied regard-
ing the date of publication, the language used or
the type of article (Table 2).
L-asparaginase is one of the drugs with asso-
ciation with AP. The first reports of L-asparaginase-
associated pancreatitis (AAP) started in the decade
of 60’s11. However, this is not a very common reac-
tion, which varies from 2 to 19%1,12-14, and fatal,
with mortality rates ranging from zero to 5% of cases
of pancreatitis4,14,15. There is no relationship of dose
or duration in treatment for pancreatitis, it usually
appears after the fourth or sixth application. How-
ever there are reports of AAP on the first applica-
tion1,2,12,16,17. Symptoms begin about 4 days after
application, but may vary from 1 to 13 days1,12,16.
Most cases of AAP occur in pediatric patients,
since it is recommended for the treatment of acute
lymphocytic leukemia. This disease affects mainly
children. Patients from 10 to 18 years old have an
increased risk of 2.4 times to develop AAP, compar-
ing with patients with less than 10 years old1. There
are no studies comparing the risk among children
and adults.
Simvastatin alone is also correlated with pan-
creatitis, however without reported deaths18-21. In
some cases it was combined with fenofibrate22 and
salicylate23, both followed by death.
The use of a drug usually generates various
compounds, which in certain cases may interact
unpredictably with tissues, leading toxicity. To bet-
ter assess whether the use of a drug is causal or
casual, this relationship is classified into certain,
probable, possible, unlikely, conditional or
unclassifiable24. Naranjo´s probability scale of ad-
verse drug reaction established the causality be-
tween these medications and AP as probable9. Sev-
eral evaluation criteria of the Naranjo’s scale could
not be evaluated because of non reexposure and
Table 2. Systematic review of the literature performed on March 29, 2014.
Electronic databases Search Strategy Found Results
PubMed‡ Asparaginase* AND Pancreatitis* 87 17 Original articles
12 Reviews
43 Case reports
4 Letters
Simvastatin* AND Pancreatitis* 12 8 Case reports
1 Letter
Asparaginase* AND Simvastatin* AND Pancreatitis* - -
Cochrane Library‡ Asparaginase AND Pancreatitis 10 3 Original articles;
2 Case reports
Simvastatin AND Pancreatitis 6 -
Lilacs Asparaginase§ AND Pancreatite§ 3 3 Case reports
Simvastatina§ AND Pancreatite§ - -
Asparaginase§ AND Sinvastatina§ AND Pancreatite§ - -
Scielo Asparaginase AND Pancreatite 1 1 Case report
Simvastatina AND Pancreatite 1 1 Review
Asparaginase AND Sinvastatina AND Pancreatite - -
‡ Search in title and abstract; * Medical Subject Headings; §Descritores em Ciências da Saúde.
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severity of the case, a fact that may have hindered
a better definition of causality. In addition, cases of
AAP described in the literature do not follow the
evolution of classical immediate onset of symptoms
and dose-response relationship.
Although there are several reports of pancrea-
titis associated with L-asparaginase and few asso-
ciated with simvastatin did not find any reports of a
possible pancreatitis caused by both these drugs,
including or others references source25,26. For this
reason, the AP is associated to L-Asparaginase, with
possibility of a synergistic effect between simvastatin
and L-Asparaginase, reinforces the importance of
pharmacovigilance of these drugs.
Conclusion
This case shows the importance of monitor-
ing patients treated with L-asparaginase, through
careful observation of clinical signs and laboratory
follow-up, as well as verification of other medica-
tions in use. The AP may have different levels of
severity, being indispensable the quick diagnosis and
early treatment.
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